Login to Your Account

Financings Roundup

Vertex Aims for $320M Offering to Push Telaprevir to the Finish

By Catherine Hollingsworth

Friday, February 20, 2009
Vertex Pharmaceuticals Inc. is likely to have a big enough pot of cash to launch telaprevir for hepatitis C virus and to advance a potential treatment for cystic fibrosis, now that it has agreed to sell 10 million new shares. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription